{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-156440","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2025-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.465284+00:00","generated_at":"2026-05-18T09:05:44.650297+00:00","sec_items":["3.02","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Recursion acquires full ownership of oral ENPP1 inhibitor program from Rallybio","bullets":["Buys Rallybio's 50% stake in ENPP1 JV, gaining full rights to REV102 for hypophosphatasia.","Initial consideration: 1,457,952 RXRX shares (~$7.5M at $5.1442 VWAP) plus cash.","Contingent milestone payments up to $12.5M in additional shares.","REV102 is a preclinical oral ENPP1 inhibitor for rare bone disorder HPP.","Deal closed July 8, 2025; resale registration filed for issued shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-156440","json":"https://secwatch.observer/filing/0001193125-25-156440.json","markdown":"https://secwatch.observer/filing/0001193125-25-156440.md","text":"https://secwatch.observer/filing/0001193125-25-156440.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000119312525156440/0001193125-25-156440-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000119312525156440/d83626d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:05:44.650297+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}